BD Announces Results For 2013 Second Fiscal Quarter

FRANKLIN LAKES, N.J., May 2, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the second fiscal quarter ended March 31, 2013, representing an increase of 3.7 percent from the prior-year period, or 4.1 percent on a foreign currency-neutral basis. 

"We continued to deliver solid performance in the second quarter. Our results for the first half of the year give us the confidence to raise guidance for fiscal year 2013," said Vincent A. Forlenza, Chairman, CEO and President. "Additionally, our recent announcements of the BD Simplist product line and the Cato Software acquisition demonstrate how we are continuing to invest in innovation both organically and through strategic acquisition opportunities. We believe we are well positioned for continued success in fiscal year 2013 and beyond."  

Company Completes Acquisition of Cato Software Solutions

As previously announced on March 12, 2013, the Company completed its acquisition of Cato Software Solutions, or "CSS."  CSS, based in Vienna, Austria, provides a suite of comprehensive medication safety software solutions that are intended to prevent medication errors and improve efficiency in both pharmacy and drug delivery settings.  CSS revenues will be reported in the BD Medical – Medical Surgical Systems unit.

Company Enters Pharmaceutical Manufacturing Market

On March 27, 2013, the Company announced its entrance into the pharmaceutical manufacturing industry with BD Simplist, a line of ready-to-administer, prefilled generic injectables. BD Simplist prefilled injectables will be commercialized and manufactured by BD Rx Inc., a wholly-owned subsidiary of BD, which plans to launch 20 to 30 drugs over the next few years. BD Rx Inc. revenues will be reported in the BD Medical – Medical Surgical Systems unit.

Second Quarter and Six-Month Fiscal 2013 Operating Results

Diluted earnings per share from continuing operations for the second quarter were $1.39, compared with $1.31 in the prior-year period, representing a 6.1 percent increase, or 7.6 percent on a foreign currency-neutral basis. Excluding the medical device tax that went into effect in January 2013 under the U.S. healthcare reform law, adjusted diluted earnings per share from continuing operations were $1.44, which represents growth of 9.9 percent. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the second quarter increased 11.5 percent.

For the six-month period ending March 31, 2013, diluted earnings per share from continuing operations were $2.74, compared with $2.45 in the prior-year period. This represents growth of 11.8 percent.  Excluding the medical device tax, adjusted diluted earnings per share from continuing operations were $2.79.  This represents growth of 13.9 percent excluding the medical device tax.  Foreign currency had an immaterial impact on earnings per share for the six-month period.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.062 billion, representing an increase of 4.0 percent compared with the prior-year period, or 4.2 percent on a foreign currency-neutral basis. The segment's revenue growth reflects solid sales in the Medical Surgical Systems and Diabetes Care units. As expected, we experienced lower revenue growth in the Pharmaceutical Systems unit, reflecting an unfavorable comparison to the prior-year period.

For the six-month period ended March 31, 2013, BD Medical revenues increased 3.7 percent, or 4.7 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $659 million, representing an increase of 4.6 percent compared with the prior-year period, or 4.9 percent on a foreign currency-neutral basis. The segment's growth was driven by new product sales as well as international expansion in the Diagnostic Systems unit.

For the six-month period ended March 31, 2013, BD Diagnostics revenues increased 4.8 percent, or 5.5 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $279 million, representing an increase of 0.6 percent compared with the prior-year period, or 1.9 percent on a foreign currency-neutral basis.  Segment revenue growth was driven by solid instrument placements in the U.S., as well as a favorable timing of orders in Advanced Bioprocessing.  This was offset in part by softness in Western Europe due to austerity measures and timing of government funding in Japan.

For the six-month period ended March 31, 2013, BD Biosciences revenues increased 1.1 percent, or 2.6 percent on a currency-neutral basis.

Geographic Results

Second quarter revenues in the U.S. of $824 million represent an increase of 0.3 percent over the prior-year period. As expected, U.S. revenues were impacted by timing of orders.  Revenues outside of the U.S. were $1.177 billion, representing an increase of 6.2 percent compared with the prior-year period, or 6.9 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and strong sales of safety-engineered products. 

For the six-month period ended March 31, 2013, revenues in the U.S. were $1.654 billion, representing an increase of 1.6 percent compared with the prior-year period. Revenues outside of the U.S. were $2.247 billion, representing an increase of 5.3 percent when compared with the prior-year period, or 7.0 percent on a foreign currency-neutral basis.

Fiscal 2013 Outlook for Full Year

The Company is raising its previously communicated guidance for the full fiscal year 2013 on revenues and earnings per share growth. On a currency-neutral basis, revenue growth is expected to be between 4.5 and 5.0 percent, or an increase of 50 basis points. Reported revenue growth guidance remains consistent with the Company's previously guided range of 3.5 to 4.0 percent. Reported diluted earnings per share from continuing operations for fiscal year 2013 are expected to be between $5.72 and $5.75, or an increase of $0.03 from the previous guidance range.  This represents growth of 6.5 to 7.0 percent over 2012 adjusted diluted earnings per share of $5.37, which excludes the pension settlement charge in fiscal year 2012. On a currency-neutral basis, earnings per share are expected to increase 100 basis points to 8.5 to 9.0 percent. After adjusting for the impact of the medical device tax and foreign currency, adjusted diluted earnings per share are expected to grow 11.0 to 11.5 percent.   In line with previously disclosed guidance, the Company plans to repurchase, subject to market conditions, about $500 million of its common stock in fiscal year 2013.

Conference Call Information

A conference call regarding BD's second quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Thursday, May 2, 2013.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-475-6701 (domestic) and 1-320-365-3844 (international) through the close of business on Thursday, May 9, 2013, confirmation number 290460.

Non-GAAP Financial Measures

This news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2013 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement.  These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures, including "sequestration", which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369









BECTON DICKINSON AND COMPANY








CONSOLIDATED INCOME STATEMENTS








(Unaudited; Amounts in thousands, except per share data)

















Three Months Ended March 31,



2013


2012


% Change










REVENUES

$

2,000,375

$

1,928,961


3.7










Cost of products sold


982,256


941,184


4.4


Selling and administrative 


514,610


487,694


5.5


Research and development


122,377


116,753


4.8


TOTAL OPERATING COSTS








     AND EXPENSES


1,619,243


1,545,631


4.8










OPERATING INCOME


381,132


383,330


(0.6)










Interest income


11,818


16,678


(29.1)


Interest expense


(34,732)


(35,140)


(1.2)


Other income, net


2,253


4,657


(51.6)










INCOME FROM CONTINUING OPERATIONS BEFORE








     INCOME TAXES


360,471


369,525


(2.5)










Income tax provision


84,351


94,401


(10.6)










INCOME FROM CONTINUING OPERATIONS


276,120


275,124


0.4










(LOSS) INCOME FROM DISCONTINUED OPERATIONS








   NET OF INCOME TAX (BENEFIT) PROVISION OF








    $(1,177) AND $7,544, RESPECTIVELY


(483)


15,909


        NM 










NET INCOME

$

275,637

$

291,033


(5.3)










EARNINGS PER SHARE
















Basic:








Income from continuing operations

$

1.42

$

1.33


6.8


(Loss) income from discontinued operations

$

-

$

0.08


        NM 


Net income 

$

1.42

$

1.41


0.7










Diluted:








Income from continuing operations

$

1.39

$

1.31


6.1


(Loss) income from discontinued operations

$

-

$

0.08


        NM 


Net income 

$

1.39

$

1.39


-


















AVERAGE SHARES OUTSTANDING
















     Basic


194,609


206,426




     Diluted


198,143


209,803












NM - Not Meaningful








 

 

BECTON DICKINSON AND COMPANY








CONSOLIDATED INCOME STATEMENTS








(Unaudited; Amounts in thousands, except per share data)

















Six Months Ended March 31,



2013


2012


% Change










REVENUES

$

3,900,567

$

3,760,681


3.7










Cost of products sold


1,876,319


1,841,649


1.9


Selling and administrative 


1,010,489


969,964


4.2


Research and development


240,538


228,981


5.0


TOTAL OPERATING COSTS








     AND EXPENSES


3,127,346


3,040,594


2.9










OPERATING INCOME


773,221


720,087


7.4










Interest income


19,740


32,126


(38.6)


Interest expense


(69,761)


(64,518)


8.1


Other income, net


2,967


4,272


(30.5)










INCOME FROM CONTINUING OPERATIONS BEFORE








     INCOME TAXES


726,167


691,967


4.9










Income tax provision


179,797


168,298


6.8










INCOME FROM CONTINUING OPERATIONS


546,370


523,669


4.3










INCOME FROM DISCONTINUED OPERATIONS








   NET OF INCOME TAX PROVISION OF








    $215,160 AND $14,871, RESPECTIVELY


354,703


30,350


        NM 










NET INCOME

$

901,073

$

554,019


62.6










EARNINGS PER SHARE
















Basic:








Income from continuing operations

$

2.79

$

2.49


12.0


Income from discontinued operations

$

1.81

$

0.14


        NM 


Net income (1)

$

4.61

$

2.63


75.3










Diluted:








Income from continuing operations

$

2.74

$

2.45


11.8


Income from discontinued operations

$

1.78

$

0.14


        NM 


Net income (1)

$

4.53

$

2.59


74.9


















AVERAGE SHARES OUTSTANDING
















     Basic


195,528


210,385




     Diluted


199,068


213,970












NM - Not Meaningful








(1) Total per share amounts may not add due to rounding.
















 

 

BECTON DICKINSON AND COMPANY








SUPPLEMENTAL REVENUE INFORMATION








REVENUES BY SEGMENT AND GEOGRAPHIC AREA








(Unaudited; Amounts in thousands)

















Three Months Ended March 31,



2013


2012


% Change










BD MEDICAL








   United States

$

412,485

$

418,521


(1.4)


   International


649,586


602,666


7.8


TOTAL

$

1,062,071

$

1,021,187


4.0










BD DIAGNOSTICS








   United States

$

322,217

$

318,597


1.1


   International


336,723


311,422


8.1


TOTAL

$

658,940

$

630,019


4.6










BD BIOSCIENCES








   United States

$

88,862

$

83,986


5.8


   International


190,502


193,769


(1.7)


TOTAL

$

279,364

$

277,755


0.6










TOTAL REVENUES








   United States

$

823,564

$

821,104


0.3


   International


1,176,811


1,107,857


6.2


TOTAL

$

2,000,375

$

1,928,961


3.7


































BECTON DICKINSON AND COMPANY








SUPPLEMENTAL REVENUE INFORMATION








REVENUES BY SEGMENT AND GEOGRAPHIC AREA








(Unaudited; Amounts in thousands)

















Six Months Ended March 31,



2013


2012


% Change










BD MEDICAL








   United States

$

837,851

$

833,190


0.6


   International


1,207,593


1,138,394


6.1


TOTAL

$

2,045,444

$

1,971,584


3.7










BD DIAGNOSTICS








   United States

$

642,757

$

630,220


2.0


   International


668,108


620,542


7.7


TOTAL

$

1,310,865

$

1,250,762


4.8










BD BIOSCIENCES








   United States

$

173,057

$

163,913


5.6


   International


371,201


374,422


(0.9)


TOTAL

$

544,258

$

538,335


1.1










TOTAL REVENUES








   United States

$

1,653,665

$

1,627,323


1.6


   International


2,246,902


2,133,358


5.3


TOTAL

$

3,900,567

$

3,760,681


3.7































BECTON DICKINSON AND COMPANY







SUPPLEMENTAL REVENUE INFORMATION







REVENUES BY BUSINESS SEGMENTS AND UNITS







Three Months Ended March 31,







(Unaudited; Amounts in thousands)















United States



2013


2012


 % Change 








BD MEDICAL







   Medical Surgical Systems

$

235,624

$

237,599


(0.8)

   Diabetes Care


106,643


105,725


0.9

   Pharmaceutical Systems


70,218


75,197


(6.6)

TOTAL

$

412,485

$

418,521


(1.4)








BD DIAGNOSTICS







   Preanalytical Systems

$

161,967

$

163,455


(0.9)

   Diagnostic Systems


160,250


155,142


3.3

TOTAL

$

322,217

$

318,597


1.1








BD BIOSCIENCES 

$

88,862

$

83,986


5.8








TOTAL UNITED STATES

$

823,564

$

821,104


0.3















 

























BECTON DICKINSON AND COMPANY








SUPPLEMENTAL REVENUE INFORMATION








REVENUES BY BUSINESS SEGMENTS AND UNITS








Three Months Ended March 31, (continued)








(Unaudited; Amounts in thousands)





















International








 % Change 




2013


2012


 Reported 


FXN


FX Impact














BD MEDICAL












   Medical Surgical Systems

$

302,941

$

281,340


7.7


8.4


(0.7)


   Diabetes Care


125,449


113,520


10.5


12.0


(1.5)


   Pharmaceutical Systems


221,196


207,806


6.4


5.7


0.7


TOTAL

$

649,586

$

602,666


7.8


8.2


(0.4)














BD DIAGNOSTICS












   Preanalytical Systems

$

168,064

$

159,858


5.1


5.3


(0.2)


   Diagnostic Systems


168,659


151,564


11.3


12.4


(1.1)


TOTAL

$

336,723

$

311,422


8.1


8.8


(0.7)














BD BIOSCIENCES 

$

190,502

$

193,769


(1.7)


0.2


(1.9)














TOTAL INTERNATIONAL

$

1,176,811

$

1,107,857


6.2


6.9


(0.7)


























 

BECTON DICKINSON AND COMPANY









SUPPLEMENTAL REVENUE INFORMATION






REVENUES BY BUSINESS SEGMENTS AND UNITS








Three Months Ended March 31, (continued)









(Unaudited; Amounts in thousands)






















Total








 % Change 




2013


2012


 Reported 


FXN


FX Impact














BD MEDICAL 












   Medical Surgical Systems

$

538,565

$

518,939


3.8


4.2


(0.4)


   Diabetes Care


232,092


219,245


5.9


6.6


(0.7)


   Pharmaceutical Systems


291,414


283,003


3.0


2.4


0.6


TOTAL

$

1,062,071

$

1,021,187


4.0


4.2


(0.2)














BD DIAGNOSTICS












   Preanalytical Systems

$

330,031

$

323,313


2.1


2.2


(0.1)


   Diagnostic Systems


328,909


306,706


7.2


7.8


(0.6)


TOTAL

$

658,940

$

630,019


4.6


4.9


(0.3)














BD BIOSCIENCES 

$

279,364

$

277,755


0.6


1.9


(1.3)














TOTAL REVENUES

$

2,000,375

$

1,928,961


3.7


4.1


(0.4)


























 









BECTON DICKINSON AND COMPANY








SUPPLEMENTAL REVENUE INFORMATION








REVENUES BY BUSINESS SEGMENTS AND UNITS








Six Months Ended March 31,








(Unaudited; Amounts in thousands)

















United States




2013


2012


 % Change 










BD MEDICAL








   Medical Surgical Systems

$

484,816

$

486,015


(0.2)


   Diabetes Care


219,047


211,251


3.7


   Pharmaceutical Systems


133,988


135,924


(1.4)


TOTAL

$

837,851

$

833,190


0.6










BD DIAGNOSTICS








   Preanalytical Systems

$

328,916

$

325,570


1.0


   Diagnostic Systems


313,841


304,650


3.0


TOTAL

$

642,757

$

630,220


2.0










BD BIOSCIENCES 

$

173,057

$

163,913


5.6










TOTAL UNITED STATES

$

1,653,665

$

1,627,323


1.6










 

BECTON DICKINSON AND COMPANY









SUPPLEMENTAL REVENUE INFORMATION








REVENUES BY BUSINESS SEGMENTS AND UNITS








Six Months Ended March 31, (continued)









(Unaudited; Amounts in thousands)






















International








 % Change 




2013


2012


 Reported 


FXN


FX Impact














BD MEDICAL












   Medical Surgical Systems

$

589,687

$

555,234


6.2


7.8


(1.6)


   Diabetes Care


255,847


233,913


9.4


11.7


(2.3)


   Pharmaceutical Systems


362,059


349,247


3.7


4.8


(1.1)


TOTAL

$

1,207,593

$

1,138,394


6.1


7.7


(1.6)














BD DIAGNOSTICS












   Preanalytical Systems

$

335,882

$

314,365


6.8


8.1


(1.3)


   Diagnostic Systems


332,226


306,177


8.5


10.1


(1.6)


TOTAL

$

668,108

$

620,542


7.7


9.1


(1.4)














BD BIOSCIENCES 

$

371,201

$

374,422


(0.9)


1.2


(2.1)














TOTAL INTERNATIONAL

$

2,246,902

$

2,133,358


5.3


7.0


(1.7)














 

BECTON DICKINSON AND COMPANY










SUPPLEMENTAL REVENUE INFORMATION










REVENUES BY BUSINESS SEGMENTS AND UNITS








Six Months Ended March 31, (continued)









(Unaudited; Amounts in thousands)






















Total








 % Change 




2013


2012


 Reported 


FXN


FX Impact














BD MEDICAL 












   Medical Surgical Systems

$

1,074,503

$

1,041,249


3.2


4.0


(0.8)


   Diabetes Care


474,894


445,164


6.7


7.9


(1.2)


   Pharmaceutical Systems


496,047


485,171


2.2


3.1


(0.9)


TOTAL

$

2,045,444

$

1,971,584


3.7


4.7


(1.0)














BD DIAGNOSTICS












   Preanalytical Systems

$

664,798

$

639,935


3.9


4.5


(0.6)


   Diagnostic Systems


646,067


610,827


5.8


6.6


(0.8)


TOTAL

$

1,310,865

$

1,250,762


4.8


5.5


(0.7)














BD BIOSCIENCES 

$

544,258

$

538,335


1.1


2.6


(1.5)














TOTAL REVENUES

$

3,900,567

$

3,760,681


3.7


4.7


(1.0)














 

 

BECTON DICKINSON AND COMPANY










SUPPLEMENTAL REVENUE INFORMATION










SAFETY REVENUES










(Unaudited; Amounts in thousands)





















Three Months Ended March 31,








 % Change 




2013


2012


 Reported 


FXN


FX Impact














TOTAL SAFETY REVENUES












   United States

$

287,369

$

282,733


1.6


1.6


-


   International


227,066


205,369


10.6


11.1


(0.5)


TOTAL

$

514,435

$

488,102


5.4


5.6


(0.2)














BY SEGMENT












   BD Medical

$

256,346

$

235,928


8.7


9.0


(0.3)


   BD Diagnostics


258,089


252,174


2.3


2.4


(0.1)


TOTAL

$

514,435

$

488,102


5.4


5.6


(0.2)































































Six Months Ended March 31,








 % Change 




2013


2012


 Reported 


FXN


FX Impact














TOTAL SAFETY REVENUES












   United States

$

578,312

$

573,345


0.9


0.9


-


   International


447,299


402,326


11.2


12.7


(1.5)


TOTAL

$

1,025,611

$

975,671


5.1


5.7


(0.6)














BY SEGMENT












   BD Medical

$

508,202

$

475,711


6.8


7.5


(0.7)


   BD Diagnostics


517,409


499,960


3.5


4.1


(0.6)


TOTAL

$

1,025,611

$

975,671


5.1


5.7


(0.6)














 

BECTON DICKINSON AND COMPANY








SUPPLEMENTAL INFORMATION









Quarter-to-Date Fiscal 2013 Reconciliation - FX Impact








(Unaudited; Amounts in millions, except per share data)























Three Months Ended March 31,



Reported


Reported


Reported Growth 


Foreign Currency


FXN


FXN 




FY2013


FY2012


$


Translation


 Change 


Growth
















REVENUES

$

2,000

$

1,929

$

71

$

(8)

$

79


4.1%
















Diluted Earnings per Share














from Continuing Operations

$

1.39

$

1.31

$

0.08

$

(0.02)

$

0.10


7.6%












































FXN = Foreign Currency Neutral














All figures rounded. Totals may not add due to rounding.


































































BECTON DICKINSON AND COMPANY











SUPPLEMENTAL INFORMATION











Year-to-Date Fiscal 2013 Reconciliation - FX Impact










(Unaudited; Amounts in millions, except per share data)

























Six Months Ended March 31,



Reported


Reported


Reported Growth 


Foreign Currency


FXN


FXN 




FY2013


FY2012


$


Translation


 Change 


Growth
















REVENUES

$

3,901

$

3,761

$

140

$

(35)

$

175


4.7%
















Diluted Earnings per Share














from Continuing Operations

$

2.74

$

2.45

$

0.29

$

0.00

$

0.29


11.8%












































FXN = Foreign Currency Neutral













All figures rounded. Totals may not add due to rounding.










 

 

BECTON DICKINSON AND COMPANY








SUPPLEMENTAL INFORMATION







FY2013 Quarter-to-Date Reconciliation







(Unaudited; Amounts in millions, except per share data)




















Three Months Ended March 31,



Reported


Medical Device


Adjusted


Reported


Adjusted




FY 2013


Excise Tax(1)


FY 2013


FY 2012


%Growth














Diluted Earnings per Share












from Continuing Operations

$

1.39

$

0.05

$

1.44

$

1.31


9.9%






































(1) Represents the medical device excise tax which went into effect in January 2013




    under the U.S. Patient Protection and Affordable Care Act.








































All figures rounded. Totals may not add due to rounding.




















































BECTON DICKINSON AND COMPANY






SUPPLEMENTAL INFORMATION







FY2013 Year-to-Date Reconciliation








(Unaudited; Amounts in millions, except per share data)





















Six Months Ended March 31,



Reported


Medical Device


Adjusted


Reported


Adjusted




FY 2013


Excise Tax(1)


FY 2013


FY 2012


%Growth














Diluted Earnings per Share












from Continuing Operations

$

2.74

$

0.05

$

2.79

$

2.45

$

13.9%






































(1) Represents the medical device excise tax which went into effect in January 2013




    under the U.S. Patient Protection and Affordable Care Act.








































All figures rounded. Totals may not add due to rounding.





 

 

BECTON DICKINSON AND COMPANY








SUPPLEMENTAL INFORMATION






Quarter-to-Date Fiscal 2013 Reconciliation - Adjusted FX Impact



(Unaudited; Amounts in millions, except per share data)



















Three Months Ended March 31,



Adjusted


Reported


Adjusted
Growth 


Foreign
Currency


FXN


FXN 




FY 2013


FY 2012


$


Translation


 Change 


Growth
















Diluted Earnings per Share














from Continuing Operations

$

1.44

$

1.31

$

0.13

$

(0.02)

$

0.15


11.5%












































FXN = Foreign Currency Neutral







All figures rounded. Totals may not add due to rounding.
































































BECTON DICKINSON AND COMPANY










SUPPLEMENTAL INFORMATION










Year-to-Date Fiscal 2013 Reconciliation - Adjusted FX Impact







(Unaudited; Amounts in millions, except per share data)






















Six Months Ended March 31,



Adjusted


Reported


Adjusted
Growth 


Foreign
Currency


FXN


FXN 




FY 2013


FY 2012


$


Translation


 Change 


Growth
















Diluted Earnings per Share














from Continuing Operations

$

2.79

$

2.45

$

0.34

$

0.00

$

0.34


13.9%












































FXN = Foreign Currency Neutral









All figures rounded. Totals may not add due to rounding.







 


BECTON DICKINSON AND COMPANY







SUPPLEMENTAL INFORMATION







FY2013 Outlook Reconciliation









Reported







Basis


FX Impact


FXN Basis








Revenues - Full Year 2013 estimated growth


3.5% - 4.0%


(1.0%)


4.5% - 5.0%